Health · STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Autoimmune cell therapy trials face growing safety scrutiny after patient deaths
Why it matters
Recent patient fatalities in early-stage clinical trials highlight persistent safety risks and uncertainties surrounding emerging cell and CAR-T therapies for autoimmune conditions.
The brief
STAT News reported that Bristol Myers Squibb announced a patient death in a Phase 1 trial testing an experimental CAR-T therapy for multiple sclerosis.[1] According to STAT News, the participant developed unresolved motor symptoms and subsequently succumbed to septic pneumonia following immunosuppressant treatment, though the company noted previous medical complications complicate the direct attribution of the root cause.[2][3] In a separate development reported by STAT News, Artiva Biotherapeutics decided to wind down operations after two patient fatalities occurred in a Phase 2 trial evaluating an NK cell therapy for autoimmune diseases.[4] STAT News noted that the company attributed the first death to a pre-treatment chemotherapy regimen rather than the cell therapy itself, while the cause of the second participant's sudden death roughly two months post-treatment remains undetermined.[5][6] Reporting from STAT News indicates that the exact role of the experimental treatments in these fatalities requires further clinical clarification.
What we don’t know yet
- Bristol Myers Squibb announced a patient death in a Phase 1 trial testing an experimental CAR-T therapy for multiple sclerosis. Only statnews.com reports this so far.
- The participant in the Bristol Myers Squibb trial developed unresolved motor symptoms and succumbed to septic pneumonia following immunosuppressant treatment. Only statnews.com reports this so far.
- Bristol Myers Squibb noted previous medical complications complicate the direct attribution of the root cause of the death. Only statnews.com reports this so far.
- Artiva Biotherapeutics decided to wind down operations after two patient fatalities occurred in a Phase 2 trial evaluating an NK cell therapy for autoimmune diseases. Only statnews.com reports this so far.
Quick answers
- What happened?
- STAT News reported that Bristol Myers Squibb announced a patient death in a Phase 1 trial testing an experimental CAR-T therapy for multiple sclerosis. According to STAT News, the participant developed unresolved motor symptoms and subsequently succumbed to septic pneumonia following immunosuppressant treatment, though the company noted previous medical complications complicate the direct attribution of the root cause. In a separate development reported by STAT News, Artiva Biotherapeutics decided to wind down operations after two patient fatalities occurred in a Phase 2 trial evaluating an NK cell therapy for autoimmune diseases. STAT News noted that the company attributed the first death to a pre-treatment chemotherapy regimen rather than the cell therapy itself, while the cause of the second participant's sudden death roughly two months post-treatment remains undetermined. Reporting from STAT News indicates that the exact role of the experimental treatments in these fatalities requires further clinical clarification.
- Why does it matter?
- Recent patient fatalities in early-stage clinical trials highlight persistent safety risks and uncertainties surrounding emerging cell and CAR-T therapies for autoimmune conditions.
- How was "Autoimmune cell therapy trials face growing safety scrutiny after patient deaths" verified?
- Citelink grounded this brief in 2 sources, including STAT News. Every claim links to its citation in the sources list below.
Grounding — every claim checked against sources
of 6 grounded4Bristol Myers Squibb announced a patient death in a Phase 1 trial testing an experimental CAR-T therapy for multiple sclerosis.
The participant in the Bristol Myers Squibb trial developed unresolved motor symptoms and succumbed to septic pneumonia following immunosuppressant treatment.
Bristol Myers Squibb noted previous medical complications complicate the direct attribution of the root cause of the death.
Artiva Biotherapeutics decided to wind down operations after two patient fatalities occurred in a Phase 2 trial evaluating an NK cell therapy for autoimmune diseases.
Artiva Biotherapeutics attributed the first death to a pre-treatment chemotherapy regimen rather than the cell therapy itself.
The cause of the second participant's sudden death roughly two months post-treatment in the Artiva Biotherapeutics trial remains undetermined.
Don't take our word for it
Run any claim in this Brief through Citelink's verification engine yourself.
Sources
How this brief was made
Citelink’s automated pipeline wrote this summary from the 2 sources listed above, then checked each claim against them before publishing. Briefs are not individually reviewed by a person before they go live, so read the original reporting for the full story.
Spotted an error? Request a correction · Corrections policy